Search
Search Results
-
Role of Myc in Brain Tumor Development
First-time N-myc amplification was reported in malignant astrocytoma (Garson et al. 1985). Myc is a family of proto-oncogenes. There are three...
-
The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer
BackgroundChemoresistance presents a significant obstacle in the treatment of colorectal cancer (CRC), yet the molecular basis underlying CRC...
-
MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch
The transcription factor MYC is overexpressed in most cancers, where it drives multiple hallmarks of cancer progression. MYC is known to promote...
-
Acetylation of c-Myc at Lysine 148 Protects Neurons After Ischemia
This study focuses on understanding the role of c-Myc, a cancer-associated transcription factor, in the penumbra following ischemic stroke. While its...
-
STK16 promoted colorectal cancer progress in a c-MYC signaling-dependent manner
BackgroundColorectal cancer standed as a global health challenge, ranking third in cancer incidence and second in cancer-related deaths worldwide. A...
-
PICH deficiency limits the progression of MYC-induced B-cell lymphoma
Plk1-interacting checkpoint helicase (PICH) is a DNA translocase involved in resolving ultrafine anaphase DNA bridges and, therefore, is important to...
-
SIRT5 promote malignant advancement of chordoma by regulating the desuccinylation of c-myc
Chordoma is a relatively rare and locally aggressive malignant tumor. Sirtuin (SIRT)5 plays pivotal roles in various tumors, but the role of SIRT5 in...
-
Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma
BackgroundMedulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor prognoses and therapy resistance....
-
Cuproptosis engages in c-Myc-mediated breast cancer stemness
BackgroundIntra-tumoral heterogeneity (ITH) is a distinguished hallmark of cancer, and cancer stem cells (CSCs) contribute to this malignant...
-
A microdeletion event at 19q13.43 in IDH-mutant astrocytomas is strongly correlated with MYC overexpression
MYC dysregulation is pivotal in the onset and progression of IDH-mutant gliomas, mostly driven by copy-number alterations, regulatory element...
-
RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common fatal cancers worldwide, and the identification of novel treatment targets and prognostic...
-
Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway
The “undruggable” MYC oncoproteins are deregulated in 70% human cancers. The approval of DFMO, an irreversible inhibitor of ornithine oxidase (ODC1)...
-
MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
Group 3 medulloblastoma is one of the most aggressive types of childhood brain tumors. Roughly 30% of cases carry genetic alterations in MYC , SMARCA4 ,...
-
NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling
BackgroundProstate cancer (PCa) is the second leading cause of cancer-related mortality among men worldwide, and its incidence has risen...
-
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
High-grade B-cell lymphoma (HGBCL), the subtype of non-Hodgkin lymphoma, to be relapsed or refractory in patients after initial therapy or salvage...
-
A novel protein FNDC3B-267aa encoded by circ0003692 inhibits gastric cancer metastasis via promoting proteasomal degradation of c-Myc
BackgroundGastric cancer (GC) ranks fifth in global cancer incidence and third in mortality rate among all cancer types. Circular RNAs (circRNAs)...
-
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness
BackgroundGastric cancer (GC) tumorigenesis and treatment failure are caused by cancer stem cells. Polypyrimidine tract binding protein 1 (PTBP1) was...
-
Myc inhibition tips the immune balance to promote antitumor immunity
Aberrant expression of Myc is one of the most common oncogenic events in human cancers. Scores of Myc inhibitors are currently under development for...
-
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and...
-
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
BackgroundSmall cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J...
